NeurologyOnline.net

Neurology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Neurobase.it

Longer-term data from the phase III open-label extension studies of OPERA I, OPERA II and ORATORIO have shown that patients who were treated with Ocrelizumab ( Ocrevus) continuously for six years or m ...


Venous percutaneous transluminal angioplasty ( vPTA ) in patients with multiple sclerosis ( MS ) and chronic cerebrospinal venous insufficiency ( CCSVI ) have shown contradictory results. The aim of ...


Tthe FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) an oral medication for the acute treatment of migraine, with or without aura, in adults. Reyvow has a unique mechani ...


A large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor ( TNF ) blocking agent reduc ...


Positive results for Ofatumumab ( OMB157 ) from the phase III ASCLEPIOS I and II studies were announced. In both head-to-head studies, Ofatumumab has demonstrated superiority over Teriflunomide ( Auba ...


People who report an elevated number of depression symptoms may be more likely to have a stroke years later than people with no depression symptoms or a low number of depression symptoms, according to ...


Current guidelines recommend lowering cholesterol for heart disease risk reduction. New findings have indicated that if cholesterol dips too low, it may boost the risk of hemorrhagic stroke. Over a ...


Ocrelizumab ( Ocrevus ) is a CD20+ B cell-selective monoclonal antibody approved for treatment of relapsing multiple sclerosis ( RMS ) and primary progressive multiple sclerosis ( PPMS ). Ocrelizum ...


Ocrelizumab ( Ocrevus ) is an infusible humanized monoclonal antibody that selectively depletes CD20+ B cells. Infusion-related reactions ( IRRs ) were summarized from the OPERA I, OPERA II, and ORA ...


Ocrelizumab ( Ocrevus ) was approved for the treatment of relapsing multiple sclerosis ( RMS ) and primary progressive multiple sclerosis ( PPMS ) by the FDA ( US Food and Drug Administration ) in Mar ...


The aim of the study was to evaluate whether Fingolimod [ Gilenya ] ( 0.5 mg and 0.25 mg ) has superior efficacy compared to Glatiramer acetate 20 mg in reducing disease activity over 12 months in pat ...


A study has evaluated the efficacy, safety, and tolerability of Atogepant versus placebo in a phase 2b/3 trial for prevention of episodic migraine. Atogepant is a novel, oral CGRP receptor antagoni ...


Novel therapeutic options with improved efficacy and safety profiles are needed for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related peptide ( CGRP ) signaling ...


A meta-analysis of phase III, randomised, placebo-controlled trials has assessed the benefits and harms of Pregabalin ( Lyrica ) in the management of neuropathic pain in adults aged 18 years and above ...


There are increasing data that delaying starting disease-modifying drugs and/or routinely stopping all disease-modifying drugs prepregnancy or immediately postconception is associated with increased r ...